A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection

NCT00000823 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

85

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Zidovudine
DRUG: Didanosine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]